Pitavastatin has been introduced more recently in the market in some but not all countries and no references are available so far when PubMed is searched with “pitavastatin” + “new-onset diabetes”, whereas some information are available on its impact on glycometabolic parameters. Overall, pitavastatin appears to be at least neutral [35]